Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 71-75, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rong, H.
Right arrow Articles by Bucht, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rong, H.
Right arrow Articles by Bucht, E.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1997;43:71-75.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

Two-site immunofluorometric assay of intact salmon calcitonin with improved sensitivity

Haiqin Rong, Leonard J Deftos1, Hong Ji and Elisabet Buchta

Department of Molecular Medicine, Endocrine and Diabetes Unit, Karolinska Hospital and Institute, S-171 76 Stockholm, Sweden.
1 Department of Medicine, University of California, San Diego and the San Diego VA Medical Center, La Jolla, CA 91261.
a Address correspondence to this author at: Department of Molecular Medicine, The Endocrine and Diabetes Unit, Karolinska Hospital, L1:02, S-171 76 Stockholm, Sweden. Fax 46-8-30 34 58; email bucht{at}enk.ks.se

We recently developed a two-site immunofluorometric assay (IFMA) of salmon calcitonin (SCT) by DELFIA (dissociation enhancement lanthanide fluoroimmunoassay) technique using the same polyclonal antibodies both for "catching" the antigen and for signaling. In the present study we used a monoclonal antibody to SCT 1–11 as the capture antibody. This antibody was biotinylated before use in streptavidin-coated microtitration plates. The polyclonal antibody labeled with Eu chelate was used as a signaling marker. This combination of antibodies resulted in an assay that was three to four times more sensitive than the previous IFMA, with a detection limit of 0.3 pmol/L serum. Intact SCT 1–32 was detected by the assay (recoveries 94–96%), but not the fragments SCT 1–11 and SCT 10–32 or human calcitonin. Dilutions of plasma samples containing SCT were parallel to the calibration curve of SCT 1–32. Pharmacokinetic studies of SCT, 100 IU administered intramuscularly to 10 men, indicated peak serum concentrations of 32–128 pmol/L within 10–20 min with apparent half-life of 56 ± 18 min (mean ± SD). This new assay will allow study of the pharmacokinetics of new calcitonin preparations that do not require injection.


Key Words: indexing terms: fluorometry • lanthanide






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.